Carteron N L
California Pacific Medical Center, 2100 Webster Street, Suite 200, San Francisco, CA 94115-2374, USA.
Mol Med Today. 2000 Aug;6(8):315-23. doi: 10.1016/s1357-4310(00)01757-3.
Biological agents that inhibit the activity of proinflammatory cytokines are being investigated for use in the treatment of rheumatoid arthritis. Thus far, two of these agents, both of which neutralize tumor necrosis factor alpha (TNF-alpha), have received US Food and Drug Administration approval for the treatment of the disease. Etanercept is a bioengineered fusion protein of the p75 soluble TNF receptor, and infliximab is a chimeric monoclonal antibody to TNF-alpha. Other agents that target proinflammatory cytokines are also being developed. By allowing earlier treatment and better-tolerated long-term therapy, biologics might help slow or prevent disease progression and joint destruction.
抑制促炎细胞因子活性的生物制剂正在被研究用于治疗类风湿性关节炎。到目前为止，其中两种制剂均已获得美国食品药品监督管理局批准用于治疗该疾病，这两种制剂都能中和肿瘤坏死因子α（TNF-α）。依那西普是一种p75可溶性TNF受体的生物工程融合蛋白，英夫利昔单抗是一种抗TNF-α的嵌合单克隆抗体。其他靶向促炎细胞因子的制剂也在研发中。通过实现更早治疗和耐受性更好的长期治疗，生物制剂可能有助于减缓或预防疾病进展和关节破坏。
